Switch theme
Sign up to access all valuation multiples
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
2014
23
LTM Revenue $0.5M
Last FY EBITDA -$61.3M
-$9.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ovid Therapeutics has a last 12-month revenue (LTM) of $0.5M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Ovid Therapeutics achieved revenue of $0.6M and an EBITDA of -$61.3M.
Ovid Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ovid Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.5M | XXX | $0.6M | XXX | XXX | XXX |
| Gross Profit | $0.5M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$61.3M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -10825% | XXX | XXX | XXX |
| EBIT | -$56.1M | XXX | -$61.9M | XXX | XXX | XXX |
| EBIT Margin | -12111% | XXX | -10934% | XXX | XXX | XXX |
| Net Profit | -$33.9M | XXX | -$26.4M | XXX | XXX | XXX |
| Net Margin | -7324% | XXX | -4670% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Ovid Therapeutics's stock price is $0.
Ovid Therapeutics has current market cap of $19.4M, and EV of -$9.2M.
See Ovid Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$9.2M | $19.4M | XXX | XXX | XXX | XXX | $-0.47 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Ovid Therapeutics has market cap of $19.4M and EV of -$9.2M.
Ovid Therapeutics's trades at -16.2x EV/Revenue multiple, and 0.1x EV/EBITDA.
Equity research analysts estimate Ovid Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ovid Therapeutics has a P/E ratio of -0.6x.
See valuation multiples for Ovid Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $19.4M | XXX | $19.4M | XXX | XXX | XXX |
| EV (current) | -$9.2M | XXX | -$9.2M | XXX | XXX | XXX |
| EV/Revenue | -19.8x | XXX | -16.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 0.1x | XXX | XXX | XXX |
| EV/EBIT | 0.2x | XXX | 0.1x | XXX | XXX | XXX |
| EV/Gross Profit | -19.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.6x | XXX | -0.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOvid Therapeutics's last 12 month revenue growth is -30%
Ovid Therapeutics's revenue per employee in the last FY averaged $25K, while opex per employee averaged $2.7M for the same period.
Ovid Therapeutics's rule of 40 is -14758% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ovid Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Ovid Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -30% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -10825% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -14758% | XXX | -10856% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $25K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6496% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 11034% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ovid Therapeutics acquired XXX companies to date.
Last acquisition by Ovid Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Ovid Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Ovid Therapeutics founded? | Ovid Therapeutics was founded in 2014. |
| Where is Ovid Therapeutics headquartered? | Ovid Therapeutics is headquartered in United States of America. |
| How many employees does Ovid Therapeutics have? | As of today, Ovid Therapeutics has 23 employees. |
| Who is the CEO of Ovid Therapeutics? | Ovid Therapeutics's CEO is Mr. Jeremy M. Levin, D.Phil.,M.B.. |
| Is Ovid Therapeutics publicy listed? | Yes, Ovid Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Ovid Therapeutics? | Ovid Therapeutics trades under OVID ticker. |
| When did Ovid Therapeutics go public? | Ovid Therapeutics went public in 2017. |
| Who are competitors of Ovid Therapeutics? | Similar companies to Ovid Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Ovid Therapeutics? | Ovid Therapeutics's current market cap is $19.4M |
| What is the current revenue of Ovid Therapeutics? | Ovid Therapeutics's last 12 months revenue is $0.5M. |
| What is the current revenue growth of Ovid Therapeutics? | Ovid Therapeutics revenue growth (NTM/LTM) is -30%. |
| What is the current EV/Revenue multiple of Ovid Therapeutics? | Current revenue multiple of Ovid Therapeutics is -19.8x. |
| Is Ovid Therapeutics profitable? | Yes, Ovid Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
